We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Guidance Differentiates Between Postmarket Requirements, Commitments
FDA Guidance Differentiates Between Postmarket Requirements, Commitments
April 18, 2012
An FDA final guidance highlights changes to the 1938 FD&C Act that give the agency new authority to require postmarket drug studies and clinical trials and make distinctions between postmarket requirements and commitments.